Skip to main content

Dearborn Physician Summarily Suspended for Overprescribing Controlled Substances

Media Contact: LARA Communications 517-373-9280

August 17, 2017 - The Michigan Department of Licensing and Regulatory Affairs (LARA) has immediately suspended the license to practice as a medical doctor of Mohammad Derani of Dearborn, MI. LARA served an order summarily suspending Dr. Derani’s license pursuant to the Public Health Code, which provides for the summary suspension of a health professional’s license when the public health, safety, or welfare requires emergency action.

LARA filed an administrative complaint alleging commonly abused and diverted controlled substances, including alprazolam, carisoprodol, hydrocodone combination drugs, and codeine/promethazine syrup.

Prescription data from the Michigan Automated Prescription System revealed that Dr. Derani ranked among the most prolific prescribers of controlled substances in Michigan in 2015 and 2016. In the fourth quarter of 2016, Dr. Derani was among the twelve most prolific prescribers of alprazolam, carisoprodol, hydrocodone combination drugs, and codeine/promethazine syrup. Dr. Derani wrote, on average, more than 43 controlled substance prescriptions for every workday between January 1, 2015 and August 14, 2017.

An important recommendation of Gov. Snyder’s Michigan Prescription Drug and Opioid Abuse Task Force called for a more comprehensive enforcement program against licensed health professionals who participate in overprescribing. LARA’s Drug Monitoring Section works to identify, investigate and seek enhanced sanctions against licensed health care professionals who overprescribe dangerous drugs, such as opiates, for other than lawful medical purposes.

An order of summary suspension is a temporary measure to protect the public and not a final determination that a licensee has violated the Public Health Code.

For more information on LARA’s regulation of health professions in Michigan, please go to

For more information about LARA, please visit
Follow us on Twitter, or “Like” us on Facebook.